| (Values in U.S. Thousands) | Jun, 2017 | Jun, 2016 | Jun, 2015 | Jun, 2014 | Jun, 2013 |
| Sales | 3,180 | 1,480 | 1,750 | 1,840 | 1,690 |
| Sales Growth | +114.86% | -15.43% | -4.89% | +8.88% | +8,350.01% |
| Net Income | -7,060 | -45,180 | -26,910 | -12,250 | -15,640 |
| Net Income Growth | +84.37% | -67.89% | -119.67% | +21.68% | +24.04% |
Prima Biomed Ltd (PBMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company's key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia.